Reaching LDL-c targets in high-risk patients requires high-efficacy cholesterol-lowering drugs in more than 50% of cases. The results of the CHECK study.

Poli, Andrea; Casula, Manuela; Tragni, Elena; Brignoli, Ovidio; Filippi, Alessandro; Cricelli, Claudio; Catapano, Alberico L

Poli, Andrea; Casula, Manuela; Tragni, Elena; Brignoli, Ovidio; Filippi, Alessandro; Cricelli, Claudio; Catapano, Alberico L.

Affiliation

Poli A; SEFAP, University of Milan, Milan, Italy. poli@nutrition-foundation.it

Pharmacol Res ; 64(4): 393-6, 2011 Oct.

Article in En | MEDLINE | ID: mdl-21740971

Subject(s)

Cardiovascular Diseases/prevention & control; Cholesterol, LDL/metabolism; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use; Adult; Aged; Cardiovascular Diseases/epidemiology; Cholesterol, HDL/metabolism; Cohort Studies; Humans; Italy/epidemiology; Middle Aged

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Cholesterol, LDL Type of study: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Pharmacol Res Journal subject: FARMACOLOGIA Year: 2011 Document type: Article Affiliation country: Italy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google